



Journal of The Ferrata Storti Foundation

## Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation

by Francesca Lorentino, Nicoletta Sacchi, Elena Oldani, Valeria Miotti, Alessandra Picardi, Anna Maria Gallina, Pietro Crivello, Paolo Bernasconi, Riccardo Saccardi, Lucia Farina, Fabio Benedetti, Michela Cerno, Anna Grassi, Benedetto Bruno, Francesca Patriarca, Fabio Ciceri, Katharina Fleischhauer, Luca Vago, and Francesca Bonifazi.

Collaborative Groups: Gruppo Italiano per il Trapianto di Midollo Osseo, CSE e terapia cellulare (GITMO)), Italian Bone Marrow Donor Registry (IBMDR))

Haematologica 2019 [Epub ahead of print]

*Citation: Francesca Lorentino, Nicoletta Sacchi, Elena Oldani, Valeria Miotti, Alessandra Picardi, Anna Maria Gallina, Pietro Crivello, Paolo Bernasconi, Riccardo Saccardi, Lucia Farina, Fabio Benedetti, Michela Cerno, Anna Grassi, Benedetto Bruno, Francesca Patriarca, Fabio Ciceri, Katharina Fleischhauer, Luca Vago, and Francesca Bonifazi.*

*Collaborative Groups: Gruppo Italiano per il Trapianto di Midollo Osseo, CSE e terapia cellulare (GITMO)), Italian Bone Marrow Donor Registry (IBMDR)). Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation. Haematologica. 2019; 104:xxx  
doi:10.3324/haematol.2019.225177*

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.*

**LETTER TO HAEMATOLOGICA****Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation**

Francesca Lorentino<sup>1</sup>, Nicoletta Sacchi<sup>2</sup>, Elena Oldani<sup>3</sup>, Valeria Miotti<sup>4</sup>, Alessandra Picardi<sup>5,6</sup>, Anna Maria Gallina<sup>2</sup>, Pietro Crivello<sup>7</sup>, Paolo Bernasconi<sup>8</sup>, Riccardo Saccardi<sup>9</sup>, Lucia Farina<sup>10</sup>, Fabio Benedetti<sup>11</sup>, Michela Cerno□, Anna Grassi<sup>3</sup>, Benedetto Bruno<sup>12,13</sup>, Francesca Patriarca<sup>4</sup>, Fabio Ciceri<sup>1,14</sup>, Katharina Fleischhauer<sup>7,15,#</sup>, Luca Vago<sup>1,16,#</sup> and Francesca Bonifazi<sup>17,#</sup>

<sup>1</sup>Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy; <sup>2</sup>Italian Bone Marrow Donor Registry, E.O. Galliera, Genova, Italy; <sup>3</sup>Hematology and BMT Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy; <sup>4</sup>Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy; <sup>5</sup>Biomedicine and Prevention Department, Tor Vergata University, Roma, Italy; <sup>6</sup>Hematology with Stem Cell Transplant Unit, AORN A. Cardarelli, Napoli, Italy; <sup>7</sup>Institute for Experimental Cellular Therapy, Essen University Hospital, Essen, Germany; <sup>8</sup>Bone Marrow Transplant Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>9</sup>Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy; <sup>10</sup>Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; <sup>11</sup>Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy; <sup>12</sup>Department of Oncology, AOU Città della Salute e della Scienza, Torino, Italy; <sup>13</sup>Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; <sup>14</sup>Vita-Salute San Raffaele University, Milano, Italy; <sup>15</sup>German Cancer Consortium, Heidelberg, Germany; <sup>16</sup>Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy; <sup>17</sup>Institute of Hematology "L. and A. Seràgnoli", University Hospital S.Orsola-Malpighi, Bologna, Italy.

# indicates equal contribution

**TEXT WORD COUNT: 1473**

**FIGURES/TABLES/REFERENCES: 1/2/15**

**RUNNING TITLE:** Comparative Evaluation of HLA-DPB1 Mismatch Models

**Corresponding Author:**

**Prof. Katharina Fleischhauer**, Institute for Experimental Cellular Therapy, University Hospital Essen, Hufelandstraße 55, 45147 Essen, Germany, e-mail: [katharina.fleischhauer@uk-essen.de](mailto:katharina.fleischhauer@uk-essen.de).

Hematopoietic Cell Transplantation (HCT) from unrelated donors (UD) is a curative therapy for many hematologic malignancies. Donor-recipient allele-level matching at HLA-A, -B, -C, -DRB1 (8/8) is widely accepted to provide best results in terms of overall survival (OS), non-relapse mortality (NRM) and graft-versus-host disease (GvHD)<sup>1</sup>. Genotypic matching for HLA-DPB1 (DPB1) has been shown to hold limited, if any, impact on post-transplant OS, and would be challenging to adopt, due to the weak linkage disequilibrium between DPB1 and the remaining HLA class II loci. Therefore, more than 80% of 8/8-matched UD-HCT are currently DPB1-mismatched<sup>1</sup>. A number of studies have demonstrated that biological models can be used to identify selected, permissive DPB1 mismatch combinations, associated with lower clinical risks compared to their high-risk, non-permissive, counterparts<sup>2-9</sup>. Five different biological models for the assignment of DPB1 permissiveness have been identified to date, of which three are based on functional T-Cell Epitopes (TCE), while the remaining two rely on a single nucleotide polymorphism (SNP) tag for expression levels. In particular, in the *TCE3 model*, DPB1 alleles are classified into three structural groups based on variation in the peptide antigen-binding domain, which leads to functionally similar or distinct behavior in terms of T-cell alloreactivity<sup>2-5</sup>. The *TCE4 model* is identical to TCE3, except for the assignment of DPB1\*02 to a fourth, independent group<sup>4</sup>. Another derivative of TCE3 is the "*delta functional distance*" (*ΔFD*) *model*, in which a FD score is assigned to every DPB1 allele based on key polymorphic aminoacids involved in anti-DPB1 alloreactivity, and differences between the FDs of patient and donor alleles defines permissive and non-permissive pairs, respectively<sup>6,7</sup>. The SNP models, in contrast, are based on high or low expression DPB1 alleles according to a *SNP tag* in the 3' untranslated region, in which the rs9277534 A and G variant is associated with low and high DPB1 expression, respectively<sup>8-9</sup>. In the *Expression model*, this SNP tag is applied to all DPB1 alleles, while in the *DP2/DP5 model*, it is applied to 19 DPB1 alleles belonging either the DP2 or the DP5 evolutionary clade. Currently, TCE3 matching is proposed by stem cell donor registries in the US and Europe, because it is the only of these models to have been validated in independent cohorts. However, a comparative evaluation of the five different biological models for DPB1 permissiveness and their association with HCT outcome has not been undertaken so far.

Here, we have filled this gap by analysing the outcome of 422 patients with available 2<sup>nd</sup> field DPB1 typing transplanted from 8/8 HLA-A, -B, -C and -DRB1 allele matched UDs in 32 centers from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO), between 2012 and 2015. Of these, 43 pairs had a mismatch at HLA-DQB1, and 382 had one or two DPB1 mismatches. The availability of DPB1 typing did not introduce significant biases, since clinical outcomes were similar for the 422 transplants under analysis and those (n=522) performed in the same time-period and for which DPB1 typing was not available (Supplemental Tables 1a and 1b). Patient, donor and transplant characteristics are shown in Table 1. Transplants were performed for hematologic malignancies, with mostly myeloablative conditioning and peripheral blood as stem cell source. GvHD prophylaxis included anti-T-lymphocytic globulin (ATG) in most cases. Permissive and non-permissive mismatches were assigned by the IMGT webtool version 2.0 for TCE3, and manually for the other models, using the cut-off 1.64 or 2.665 for  $\Delta$ FD as described<sup>6,7</sup>; for the Expression model, the rs9277534 SNP variant was predicted by DPB1 genotype<sup>8</sup>. Statistical methods are described in the Supplements.

The five models displayed limited overlap, and TCE4 was the most restrictive one, as in this model the fewest number of pairs (36%) were classified as permissive. For the SNP models, only donor-recipient pairs with a single unidirectional DPB1 mismatch in GvH direction could be classified, leaving 153/382 (40%) and 233/382 (61%) of pairs without classification according to the Expression or the DP2/DP5 model, respectively (Figure 1A).

Donor-recipient pairs in the permissive/low risk or non-permissive/high risk groups according to all five models were comparable concerning disease- and transplant-specific characteristics (Supplemental Tables 2-6). In univariate analysis, we confirmed previous reports<sup>10</sup> that DPB1 allele mismatches were not associated with any significant difference in OS, and this was reflected by a balance between significantly higher risks of aGvHD, in the presence of markedly though not significantly lower risks of relapse (Supplemental Table 7). Of all models, only TCE4 was significantly associated with superior 3-y OS and GRFS in patients transplanted from a permissive compared with a non-permissive donor, reflected by lower 3-y cumulative incidence (CI) of extensive cGvHD and NRM (Figure 1B-E). No significant associations with clinical outcomes were

found for the TCE3 or the  $\Delta$ FD model (Supplemental Table 7). The Expression model and the DP2/DP5 model were both associated with a higher 100-day CI of grade $\geq$ 2 aGvHD, but not with any of the other clinical endpoints (Supplemental Table 7). In multivariate analysis, TCE4 permissive pairs were independently associated with superior OS and GRFS, and with lower hazards for NRM, cGvHD and extensive cGvHD. Moreover, compared to DPB1 allele matches, permissive mismatches according to all three functional models (TCE3, TCE4 and  $\Delta$ FD) had significantly lower relapse risks (Table 2). In contrast, the high-risk mismatches according to the Expression model and the DP2/DP5 model were significantly associated with grade 2-4 aGvHD, but not with NRM or OS (Table 2). Outcome associations of all clinical co-variables used in the multivariate analyses are shown in Supplemental Table 8.

Our study is the first to compare HCT outcome associations for the five major biological models of DPB1 permissiveness. The results show that the concordance on the predicted permissiveness of DPB1 mismatches among the different models is evident but far from outright, suggesting that, even if all models describe a common biological phenomenon (the alloreactivity of T-cells against incompatible DPB1 molecules), each of them may capture and emphasize only some aspects of this interaction. The outcome analyses confirm previous reports that functional DPB1 matching according to TCE is significantly associated with survival after UD-HCT<sup>2-5</sup>, while DPB1 matching according to the SNP tag predicts the risks of aGvHD<sup>8-9</sup>. In this context, TCE4 is the most restrictive but appears as the best common denominator for permissiveness/low risk in all five models. In particular, the survival benefit of TCE4-permissive transplants over their non-permissive counterparts is mainly reflected by reduced NRM and cGvHD risks, providing support to the hypothesis that leveraging on permissive DPB1 mismatches might be a promising way to reduce NRM without compromising the graft-versus-malignancy effect of allogeneic HCT.

The study has several limitations. First, the number of pairs under analysis is relatively small, in particular for the two SNP tag models where DPB1 typing of up to 61% of pairs could not be classified. However, association of these two models with aGvHD risks is in agreement with previous reports from larger studies<sup>8,9</sup>. Second, an apparent difference with previous data from larger studies<sup>3,5</sup> is the lack of association with TCE3. This might reflect the stem cell source, which

was peripheral blood in 81% of our patients while bone marrow was used in at least 50% of patients from the other studies<sup>3,5</sup>. Moreover, 91% of our patients received in vivo T-cell depletion with ATG, while this was adopted in less than 30% of patients in other studies<sup>3,5</sup>. It should also be noted that TCE4 has been previously found to be associated with OS, including an analysis of non-overlapping GITMO transplants from earlier years<sup>4</sup>, a recent study from the French Registry<sup>11</sup>, and a large multicentre study from the International Histocompatibility Workshop<sup>3</sup>. Since the latter did not show a significant advantage of TCE4 over TCE3, and DPB1 permissive donors are more frequent in TCE3, TCE3 was adopted by stem cell donor registries and not further investigated in subsequent studies<sup>5</sup>. The greater restrictiveness of TCE4 compared to TCE3 in assigning permissiveness is due to appreciation of DPB1\*02 as a separate functional group. Interestingly, HLA-DP2 is the so far only HLA-DP specificity associated with autoimmunity<sup>12</sup>, and recent evidence suggests a similar breadth of the alloreactive T cell receptor repertoire in permissive pairs involving this allele group compared to non-permissive pairs<sup>13</sup>, arguing in favor of a functional basis for TCE4.

In conclusion, our results highlight the relevance of refining transplant-associated risks according to the biological significance of HLA matching. In particular, they confirm the association between the SNP tag models and aGvHD, while TCE4 should be prioritized for its highest performance in predicting survival and non-relapse related events. Moreover, since most of TCE4 permissive donors are classified as low-risk for both SNP tag models, they may be the best alternative to favor positive overall outcomes. Clearly, additional and possibly prospective studies should be performed to provide more definitive evidence for the respective value of the five DPB1 models, also in view of emerging new strategies for GvHD prophylaxis, which could modulate the observed outcome associations.

**ACKNOWLEDGEMENTS**

The authors would like to thank all investigators and data managers for their dedicated patient care. This work was supported by the Italian Ministry of Health (RF-2011-02351998 to F.C. and L.V., RF-2011-02348034 to L.V., N.S. and A.R., and TRANSCAN HLALOSS to L.V. and K.F.), by the Associazione Italiana per la Ricerca sul Cancro (Start-Up Grant #14162 to L.V.), by the ASCO Conquer Cancer Foundation (2014 Young Investigator Award to L.V.), the Deutsche José Carreras Leukämie Stiftung (grants DJCLS R 15-02 and DJCLS 01 R/2017 to K.F.), the Josef Senker Stiftung to K.F., and by the DKMS Mechtild Harf Foundation (DKMS Mechtild Harf Research Grant 2015 to L.V. and DKMS Mechtild Harf Research Grant 2018 to P.C.).

**AUTHORSHIP**

F.L., L.V., F.C., K.F. and F.B. designed, performed, coordinated the research, collected, analyzed, interpreted clinical data, and wrote the manuscript; F.L. performed statistical analysis. L.V. prepared the figure. N.S., V.M and A.M.G. provided immunogenetic data. All authors contributed to patient clinical care and data collection, critically reviewed the manuscript and approved the final version.

**DISCLOSURES**

All the authors declare no competing financial interests.

**REFERENCES**

1. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood*. 2007;110(13):4576–4583.
2. Zino E, Frumento G, Markt S, et al. A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. *Blood*. 2004;103(4):1417–1424.
3. Fleischhauer K, Shaw BE, Gooley T, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. *Lancet Oncol*. 2012;13(4):366–374.
4. Crocchiolo R, Zino E, Vago L, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. *Blood*. 2009;114(7):1437–1444.
5. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. *Blood*. 2014;124(16):2596–2606.
6. Crivello P, Heinold A, Rebmann V, et al. Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT. *Blood*. 2016;128(1):120–129.
7. Arrieta-Bolaños E, Crivello P, Shaw BE, et al. In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance. *Blood Adv*. 2018;2(14):1773–1783.
8. Petersdorf EW, Malkki M, O'hUigin C, et al. High HLA-DP Expression and Graft-versus-Host Disease. *N Engl J Med*. 2015;373(7):599–609.
9. Morishima S, Shiina T, Suzuki S, et al. Evolutionary basis of HLA-DPB1 alleles affects acute GVHD in unrelated donor stem cell transplantation. *Blood*. 2018;131(7):808–817.
10. Shaw BE, Gooley TA, Malkki M, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. *Blood*. 2007;110(13):4560-4566.



11. Gagne K, Loiseau P, Dubois V, et al. Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study. *Bone Marrow Transplant.* 2015;50(2):232–236.
12. Dai S, Murphy GA, Crawford F, et al. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. *Proc Natl Acad Sci U S A.* 2010;107(16):7425-7430.
13. Arrieta-Bolaños E, Crivello P, Metzger M, et al. Alloreactive T cell receptor diversity against structurally similar or dissimilar HLA-DP antigens assessed by deep sequencing. *Front Immunol.* 2018;9:280.
14. Gratwohl A. The EBMT risk score. *Bone Marrow Transplant.* 2012;47(6):749–756.
15. Sorrow ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood.* 2005;106(8):2912–2919.

**Table 1. Patient, transplant and donor characteristics.**

|   | <b>Population n= 422</b> |
|---|--------------------------|
| <b>Median follow-up for survivors, years (range)</b>                | 3.2 (0.1-6)              |
| <b>Patient age, years, median (range)</b>                           | 49 (18-70)               |
| <b>Patient gender, male, n (%)</b>                                  | 244 (58%)                |
| <b>Type of diagnosis, n (%)</b>                                     |                          |
| AML   | 168 (40%)                |
| ALL   | 63 (15%)                 |
| MDS or MPN  | 69 (16%)                 |
| Lymphoma and Myeloma  | 110 (26%)                |
| CLL   | 12 (3%)                  |
| <b>Disease status according to EBMT risk<sup>14</sup>, n (%)</b>    |                          |
| Early   | 191 (45%)                |
| Intermediate  | 111 (26%)                |
| Advanced  | 120 (29%)                |
| <b>HCT-CI score<sup>15</sup>, median (range)</b>                    | 1 (0-7)                  |
| <b>Karnofsky performance status, median (range)</b>                 | 90% (50-100)             |
| <b>Donor gender, male, n (%)</b>                                    | 306 (72%)                |
| <b>N° of previous pregnancies for female donors, median (range)</b> | 0 (0-6)                  |
| <b>Female donor/male recipient, n (%)</b>                           | 61 (14%)                 |
| <b>Host/donor CMV serostatus, n(%)</b>                              |                          |
| Pos/pos   | 157 (37%)                |
| Pos/neg   | 166 (39%)                |
| Neg/pos   | 36 (9%)                  |
| Neg/neg   | 53 (13%)                 |
| Missing   | 10 (2%)                  |
| <b>Type of conditioning, n (%)</b>                                  |                          |
| MAC   | 271 (64%)                |
| RIC   | 111 (35%)                |
| <b>Source of stem cells, n (%)</b>                                  |                          |
| PB  | 343 (81%)                |
| BM  | 79 (19%)                 |
| <b>ATG-based GvHD prophylaxis, n (%)</b>                            | 382 (91%)                |
| <b>GvHD prophylaxis details:</b>                                    |                          |
| ATG+CSA+MTX   | 341 (81%)                |
| ATG+Sirolimus+MMF   | 26 (6%)                  |
| Other ATG-based prophylaxis   | 15 (4%)                  |
| CSA+MTX   | 24 (5%)                  |
| Other prophylaxis   | 16 (4%)                  |

Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasms; CLL, chronic lymphocytic leukemia; CMV, Cytomegalovirus; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; PB, peripheral blood; BM, bone marrow; ATG, anti-T-lymphocytic globulin; CSA, Cyclosporine A; MTX, Methotrexate.

**Table 2. Multivariate analysis of DPB1 mismatch models and association with HCT outcomes.**



|   | OS                   |              | GRFS                 |             | Relapse              |             | NRM                  |             | aGvHD $\geq$ 2              |              | aGvHD $\geq$ 3              |             | cGvHD                |             | Ext cGvHD            |             |
|---|----------------------|--------------|----------------------|-------------|----------------------|-------------|----------------------|-------------|-----------------------------|--------------|-----------------------------|-------------|----------------------|-------------|----------------------|-------------|
|   | HR (95% CI)          | p            | HR (95% CI)          | p           | HR (95% CI)          | p           | HR (95% CI)          | p           | HR (95% CI)                 | p            | HR (95% CI)                 | p           | HR (95% CI)          | p           | HR (95% CI)          | p           |
| <b>TCE4<sup>1</sup>: NP vs P</b>                  | <b>1.7 (1.1-2.4)</b> | <b>0.008</b> | <b>1.4 (1.1-1.9)</b> | <b>0.01</b> | 1.1 (0.7-1.7)        | 0.7         | <b>1.9 (1.1-3.2)</b> | <b>0.01</b> | 1.3 (0.8-2.1)               | 0.2          | 1.5 (0.7-3.2)               | 0.3         | <b>1.7 (1.1-2.6)</b> | <b>0.02</b> | <b>3.6 (1.4-9.5)</b> | <b>0.01</b> |
| <b>Matched vs P</b>                               | <b>2.1 (1.2-3.7)</b> | <b>0.01</b>  | 1.5 (0.9-2.4)        | 0.09        | <b>2 (1.1-3.7)</b>   | <b>0.03</b> | 2 (0.9-4.8)          | 0.09        | Not applicable <sup>6</sup> |              | Not applicable <sup>6</sup> |             | 0.8 (0.3-2)          | 0.6         | 0.9 (0.1-7.5)        | 0.9         |
| <b>TCE3<sup>2</sup>: NP vs P</b>                  | 1.1 (0.8-1.6)        | 0.5          | 1.1 (0.8-1.4)        | 0.5         | 1 (0.6-1.5)          | 0.9         | 1.1 (0.7-1.8)        | 0.6         | 1.2 (0.8-1.9)               | 0.4          | 1.4 (0.6-2.9)               | 0.4         | 1.2 (0.8-1.8)        | 0.4         | 1.7 (0.8-3.6)        | 0.1         |
| <b>Matched vs P</b>                               | 1.6 (0.9-2.7)        | 0.09         | 1.2 (0.8-1.9)        | 0.3         | <b>1.9 (1.1-3.4)</b> | <b>0.04</b> | 1.4 (0.6-3)          | 0.4         | Not applicable <sup>6</sup> |              | Not applicable <sup>6</sup> |             | 0.6 (0.2-1.5)        | 0.3         | 0.5 (0.1-3.6)        | 0.5         |
| <b><math>\Delta</math>FD<sup>3</sup>: NP vs P</b> | 1 (0.7-1.5)          | 0.8          | 1 (0.7-1.4)          | 0.9         | 1.3 (0.8-2)          | 0.3         | 0.9 (0.5-1.5)        | 0.7         | 0.9 (0.5-1.4)               | 0.6          | 0.8 (0.4-1.9)               | 0.6         | 1 (0.7-1.6)          | 0.9         | 0.9 (0.4-2.1)        | 0.9         |
| <b>Matched vs P</b>                               | 1.5 (0.9-2.5)        | 0.1          | 1.2 (0.8-1.9)        | 0.4         | <b>2 (1.1-3.6)</b>   | <b>0.02</b> | 1.3 (0.6-2.7)        | 0.5         | Not applicable <sup>6</sup> |              | Not applicable <sup>6</sup> |             | 0.6 (0.2-1.4)        | 0.2         | 0.3 (0.1-2.5)        | 0.3         |
| <b>Expression<sup>4</sup>: high vs low risk</b>   | 1 (0.6-1.6)          | 0.9          | 0.8 (0.5-1.2)        | 0.2         | 0.6 (0.3-1.1)        | 0.1         | 1.1 (0.6-2.2)        | 0.7         | <b>2.2 (1.1-4.2)</b>        | <b>0.02</b>  | 1.9 (0.6-6.2)               | 0.3         | 1.2 (0.7-2.2)        | 0.4         | 1.7 (0.6-4.5)        | 0.3         |
| <b>Matched vs low risk</b>                        | 1.6 (0.9-2.8)        | 0.08         | 1.1 (0.7-1.7)        | 0.7         | 1.4 (0.7-2.5)        | 0.3         | 1.5 (0.7-3.4)        | 0.3         | Not applicable <sup>6</sup> |              | Not applicable <sup>6</sup> |             | 0.7 (0.3-1.7)        | 0.4         | 0.5 (0.1-3.7)        | 0.3         |
| <b>DP2/DP5<sup>5</sup>: high vs low risk</b>      | 1.2 (0.5-2.5)        | 0.7          | 0.8 (0.5-1.6)        | 0.6         | 0.9 (0.4-2.2)        | 0.8         | 1.3 (0.5-3.7)        | 0.6         | <b>3.8 (1.5-9.6)</b>        | <b>0.006</b> | <b>6.9 (1.5-31)</b>         | <b>0.01</b> | 1.1 (0.4-3.1)        | 0.8         | 4.1 (1-17)           | 0.05        |
| <b>Matched vs low risk</b>                        | 1.8 (1-3.2)          | 0.05         | 1 (0.6-1.7)          | 0.9         | 1.6 (0.8-3.2)        | 0.2         | 1.5 (0.6-3.7)        | 0.3         | Not applicable <sup>6</sup> |              | Not applicable <sup>6</sup> |             | 0.5 (0.2-1.5)        | 0.2         | 0.6 (0.1-4.7)        | 0.6         |

<sup>1</sup>TCE4 NP, P and matched: N= 247, 135 and 40, respectively.<sup>2</sup>TCE3 NP, P and matched: N= 174, 208 and 40, respectively.<sup>3</sup>DFD NP, P and matched: N= 123, 259 and 40, respectively; cut-off 2.665.<sup>4</sup>Expression high risk, low risk and matched: N= 76, 153 and 40, respectively.<sup>5</sup>DP2/DP5 high risk, low risk and matched: N= 31, 118 and 40, respectively.<sup>6</sup>Not applicable since no cases of aGvHD occurred in the DPB1 matched cohort.

Abbreviations are defined in the text. Co-variables in the multivariate models included patient age, disease phase, HCT-CI, female donor to male recipient, host-donor CMV serostatus, conditioning intensity, stem cell source, ATG use, HLA-matching on 5 loci, center effect.


**FIGURE LEGEND**

**Figure 1. Comparative stratification of donor-recipient pairs according to five different biological models of DPB1 permissiveness, and outcome associations for TCE4.** A) Classification of the 382 DPB1 mismatched pairs under analysis in this study, as permissive or low risk (green) or as non-permissive or high risk (red) group according to five different biological models of permissiveness, as described in the text. For the Expression and the DP2/DP5 model, only pairs with single mismatches in the GvH direction can be stratified, the others cannot be classified (grey). The model under investigation, and the relevant numbers in each category (green, red or grey) are indicated to the left and to the right of the panel, respectively. The bottom panels show Kaplan-Meier probabilities for OS (B), GRFS (C), and CI of NRM (D) and extensive cGvHD (E) stratified for functional DPB1 matching according to TCE4 model, with permissive and non-permissive groups represented by the red and black curves, respectively.




Number at risk

|                |     |     |     |    |    |    |
|----------------|-----|-----|-----|----|----|----|
|                | 0   | 1   | 2   | 3  | 4  | 5  |
| Non-permissive | 247 | 159 | 110 | 71 | 37 | 14 |
| Permissive     | 135 | 96  | 78  | 52 | 29 | 9  |




Number at risk

|                |     |    |    |    |    |   |
|----------------|-----|----|----|----|----|---|
|                | 0   | 1  | 2  | 3  | 4  | 5 |
| Non-permissive | 247 | 96 | 64 | 39 | 23 | 8 |
| Permissive     | 135 | 70 | 53 | 31 | 18 | 6 |



Number at risk

|                |     |     |    |    |    |    |
|----------------|-----|-----|----|----|----|----|
|                | 0   | 1   | 2  | 3  | 4  | 5  |
| Non-permissive | 247 | 138 | 95 | 60 | 31 | 10 |
| Permissive     | 135 | 86  | 69 | 41 | 23 | 8  |



Number at risk

|                |     |     |    |    |    |   |
|----------------|-----|-----|----|----|----|---|
|                | 0   | 1   | 2  | 3  | 4  | 5 |
| Non-permissive | 247 | 119 | 79 | 47 | 25 | 8 |
| Permissive     | 135 | 82  | 67 | 41 | 23 | 8 |

**Clinical endpoints definitions and statistical methods.**

Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were defined and scored according to the Glucksberg and Seattle criteria, respectively<sup>1-2</sup>. NRM was defined as death from any cause while in continuous remission of the primary disease. OS was defined as the interval from HSCT to death from any cause. GRFS events were defined as grade 3–4 acute GVHD, extensive chronic GVHD, disease relapse, or death from any cause after HSCT<sup>3</sup>. Actuarial probabilities were determined at 3 years. Baseline characteristics among groups were compared using the Chi-square test for categorical variables, while the distribution of continuous variables was compared using the Mann-Whitney U test. The probabilities of OS and GRFS were estimated using the Kaplan-Meier estimator and groups were compared by the log-rank test<sup>4-5</sup>. Cumulative incidences (CI) were estimated for GvHD, NRM and relapse to accommodate competing risks, and tests of equality across groups were performed according to Gray<sup>6-7</sup>. Relapse was a competing risk for NRM, death from any cause was a competing risk for relapse. Both relapse and death from any causes were competing risks for GvHD. Multivariate analysis were built to test the independent prognostic value of DPB1 mismatch permissiveness: each DPB1 mismatch model was the main effect term and was held in all steps of model building. Cox proportional hazard models were adopted for OS and GRFS<sup>8</sup>, while Fine-Gray proportional hazard regression models for competing events were adopted for aGvHD, cGvHD, relapse and NRM. Covariates included: patient age, disease phase, HCT-CI, female donor to male recipient, host-donor CMV serostatus, conditioning intensity, stem cell source, ATG use, HLA-matching on 5 loci (HLA-A, -B, -C, -DRB1 and -DQB1), center effect (>10 HSCT performed each year Vs ≤10). Interactions between each covariate and each DPB1 mismatch model were tested and not found. In particular, no interaction was found between HLA matching on 5 loci and each model. The proportional hazard assumption was met for all variables. The type I error was fixed at 0.05. Statistical analyses were performed with R version 3.3.3 (R Development Core Team, Vienna, Austria).

1. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. *Transplantation*. 1974 Oct;18(4):295-304.
2. Lee SJ, Vogelsang G, Flowers ME. Chronic graft versus host disease. *Biol Blood Marrow Transplant*. 2003 Apr;9(4):215-33.
3. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. *Bone Marrow Transplant*. 2016;51(4):610–611.
4. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *J Am Stat Assoc*. 1958;53:457–481.
5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep*. 1966;50(3):163–170.
6. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18(6):695–706.
7. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16:1141–1154.
8. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society. Series B (Methodological)*. 1972;34(2):187–220.

**Supplemental Table 1a.** Patient, donor and transplant characteristics in DPB1 typed or non-typed cases.

|  | <b>Non-DPB1 typed<br/>(N=582)</b> | <b>DPB1 typed<br/>(N=422)</b> | <b>p</b> |
|--|-----------------------------------|-------------------------------|----------|
| <b>Median follow-up for survivors, years (range)</b> | 3.1 (0.3-6.1)                     | 3.2 (0.3-6.2)                 | 0.7      |
| <b>H SCT year, median (range)</b>                    | 2014 (2012-2015)                  | 2013 (2012-2015)              | 0.001    |
| <b>Patient age, years, median (range)</b>            | 51 (18-69)                        | 49 (18-71)                    | 0.003    |
| <b>Patient gender, male, n</b>                       | 345                               | 245                           | 0.7      |
| <b>Type of diagnosis, n</b>                          |                                   |                               | 0.2      |
| AML or ALL   | 308                               | 232                           |          |
| MDS or MPN   | 127                               | 69                            |          |
| Lymphoma or Myeloma                                  | 138                               | 109                           |          |
| CLL  | 9                                 | 12                            |          |
| <b>Disease status at HSCT, n</b>                     |                                   |                               | 0.3      |
| Early  | 293                               | 191                           |          |
| Intermediate   | 135                               | 114                           |          |
| Advanced   | 145                               | 105                           |          |
| <b>HCT-CI score, median (range)</b>                  | 1 (0-7)                           | 1 (0-7)                       | 0.1      |
| <b>Karnofsky PS, median (range)</b>                  | 90% (40-100)                      | 90% (50-100)                  | 0.4      |
| <b>Donor age, years, median (range)</b>              | 28 (18-57)                        | 29 (18-57)                    | 0.6      |
| <b>Donor gender, male, n</b>                         | 415                               | 306                           | 0.7      |
| <b>Female donor/male recipient, n</b>                | 97                                | 61                            | 0.3      |
| <b>Host/donor CMV serostatus, n</b>                  |                                   |                               | 0.3      |
| Pos/pos  | 206                               | 156                           |          |
| Pos/neg  | 266                               | 167                           |          |
| Neg/pos  | 38                                | 36                            |          |
| Neg/neg  | 72                                | 53                            |          |
| <b>Type of conditioning, n</b>                       |                                   |                               | 0.3      |
| MAC  | 390                               | 296                           |          |
| RIC  | 192                               | 126                           |          |
| <b>Source of stem cells, n</b>                       |                                   |                               | 0.1      |
| PB   | 492                               | 342                           |          |
| BM   | 90                                | 80                            |          |
| <b>ATG-based GvHD prophylaxis, n</b>                 | 476                               | 350                           | 0.6      |

**Supplemental Table 1b.** Univariate analysis for transplant outcomes in DPB1 typed or non-typed cases.<sup>1</sup>

|                        | <b>3-y OS</b> | <b>3-y GRFS</b> | <b>3-y Relapse</b> | <b>3-y NRM</b> | <b>100-d aGvHD<math>\geq</math>2</b> | <b>100-d aGvHD<math>\geq</math>3</b> | <b>3-y cGvHD</b> | <b>3-y ext cGvHD</b> |
|------------------------|---------------|-----------------|--------------------|----------------|--------------------------------------|--------------------------------------|------------------|----------------------|
| <b>DPB1 typing</b>     |               |                 |                    |                |                                      |                                      |                  |                      |
| DPB1 typed (n=422)     | 52 (46-56)    | 32 (27-36)      | 30 (25-35)         | 27 (23-31)     | 21 (17-25)                           | 7 (5-10)                             | 28 (24-32)       | 9 (6-12)             |
| Non-DPB1 typed (N=582) | 56 (52-61)    | 35 (31-39)      | 34 (30-38)         | 23 (20-29)     | 22 (18-25)                           | 7 (5-10)                             | 27 (23-30)       | 9 (6-11)             |
| p                      | 0.15          | 0.45            | 0.08               | 0.08           | 0.60                                 | 0.85                                 | 0.68             | 0.80                 |

<sup>1</sup>shown are mean percentages (range in parenthesis) for each outcome.



**Supplemental Table 2.** Patient, donor and transplant characteristics in permissive and non permissive DPB1 mismatched pairs according to the **TCE3 model**

|  | <b>Permissive (N=208)</b> | <b>Non-permissive (N=174)</b> | <b>p</b> |
|--|---------------------------|-------------------------------|----------|
| <b>Median follow-up for survivors, years (range)</b> | 3.4 (0.3-6)               | 3.1 (0.3-6)                   | 0.28     |
| <b>HSCT year, median (range)</b>                     | 2013 (2012-2015)          | 2013 (2012-2015)              | 0.12     |
| <b>Patient age, years, median (range)</b>            | 48 (18-71)                | 50 (19-66)                    | 0.49     |
| <b>Patient gender, male, n</b>                       | 101                       | 117                           | 0.72     |
| <b>Type of diagnosis, n</b>                          |                           |                               | 0.16     |
| AML or ALL   | 121                       | 85                            |          |
| MDS or MPN   | 35                        | 32                            |          |
| Lymphoma and Myeloma                                 | 52                        | 57                            |          |
| <b>Disease status at HSCT, n</b>                     |                           |                               | 0.43     |
| Early  | 100                       | 74                            |          |
| Intermediate   | 54                        | 45                            |          |
| Advanced   | 54                        | 55                            |          |
| <b>HCT-CI score, median (range)</b>                  | 0 (0-7)                   | 1 (0-5)                       | 0.97     |
| <b>Karnofsky PS, median (range)</b>                  |                           |                               | 0.39     |
| <b>Donor age, years, median (range)</b>              | 27 (19-55)                | 30 (20-56)                    | 0.23     |
| <b>Donor gender, male, n</b>                         | 149                       | 126                           | 0.87     |
| <b>Female donor/male recipient, n</b>                | 28                        | 29                            | 0.38     |
| <b>Host/donor CMV serostatus, n</b>                  | 90% (60-100)              | 90% (50-100)                  | 0.35     |
| Pos/pos  | 71                        | 71                            |          |
| Pos/neg  | 81                        | 71                            |          |
| Neg/pos  | 19                        | 11                            |          |
| Neg/neg  | 31                        | 19                            |          |
| <b>Type of conditioning, n</b>                       |                           |                               | 0.58     |
| MAC  | 150                       | 121                           |          |
| RIC  | 58                        | 53                            |          |
| <b>Source of stem cells, n</b>                       |                           |                               | 0.01     |
| PB   | 179                       | 132                           |          |
| BM   | 29                        | 42                            |          |
| <b>ATG-based GvHD prophylaxis, n</b>                 | 189                       | 156                           | 0.69     |

**Supplemental Table 3.** Patient, donor and transplant characteristics in in permissive and non permissive DPB1 mismatched pairs according to the **TCE4 model**

|  | <b>Permissive (N=135)</b> | <b>Non-permissive (N=247)</b> | <b>p</b> |
|--|---------------------------|-------------------------------|----------|
| <b>Median follow-up for survivors, years (range)</b> | 3.4 (0.3-6)               | 3.3 (0.3-6)                   | 0.17     |
| <b>H SCT year, median (range)</b>                    | 2014 (2012-2015)          | 2013 (2012-2015)              | 0.45     |
| <b>Patient age, years, median (range)</b>            | 48 (18-68)                | 49 (19-71)                    | 0.46     |
| <b>Patient gender, male, n</b>                       | 80                        | 138                           | 0.52     |
| <b>Type of diagnosis, n</b>                          |                           |                               | 0.86     |
| AML or ALL   | 75                        | 131                           |          |
| MDS or MPN   | 22                        | 45                            |          |
| Lymphoma or Myeloma                                  | 38                        | 71                            |          |
| <b>Disease status at HSCT, n</b>                     |                           |                               | 0.80     |
| Early  | 62                        | 112                           |          |
| Intermediate   | 37                        | 62                            |          |
| Advanced   | 36                        | 73                            |          |
| <b>HCT-CI score, median (range)</b>                  | 0 (0-7)                   | 1 (0-5)                       | 0.96     |
| <b>Karnofsky PS, median (range)</b>                  | 90% (70-100)              | 90% (50-100)                  | 0.77     |
| <b>Donor age, years, median (range)</b>              | 29 (19-55)                | 28 (19-56)                    | 0.68     |
| <b>Donor gender, male, n</b>                         | 94                        | 181                           | 0.45     |
| <b>Female donor/male recipient, n</b>                | 23                        | 34                            | 0.39     |
| <b>Host/donor CMV serostatus, n</b>                  |                           |                               | 0.35     |
| Pos/pos  | 50                        | 92                            |          |
| Pos/neg  | 51                        | 101                           |          |
| Neg/pos  | 15                        | 15                            |          |
| Neg/neg  | 16                        | 34                            |          |
| <b>Type of conditioning, n</b>                       |                           |                               | 0.86     |
| MAC  | 95                        | 176                           |          |
| RIC  | 40                        | 71                            |          |
| <b>Source of stem cells, n</b>                       |                           |                               | 0.03     |
| PB   | 118                       | 193                           |          |
| BM   | 17                        | 54                            |          |
| <b>ATG-based GvHD prophylaxis, n</b>                 | 127                       | 230                           | 0.13     |

**Supplemental Table 4.** Patient, donor and transplant characteristics in in permissive and non-permissive DPB1 mismatched pairs according to the **ΔFD model**<sup>1</sup>

|  | <b>&lt;2.665 (N=259)</b> | <b>≥2.665 (N=123)</b> | <b>p</b> |
|--|--------------------------|-----------------------|----------|
| <b>Median follow-up for survivors, years (range)</b> | 3.5 (0.3-6)              | 2.9 (0.3-5)           | 0.12     |
| <b>HSCT year, median (range)</b>                     | 2013 (2012-2015)         | 2014 (2012-2015)      | 0.97     |
| <b>Patient age, years, median (range)</b>            | 48 (18-71)               | 52 (19-66)            | 0.48     |
| <b>Patient gender, male, n</b>                       | 155                      | 63                    | 0.11     |
| <b>Type of diagnosis, n</b>                          |                          |                       | 0.59     |
| AML or ALL   | 144                      | 62                    |          |
| MDS or MPN   | 45                       | 22                    |          |
| Lymphoma or Myeloma                                  | 70                       | 39                    |          |
| <b>Disease status at HSCT, n</b>                     |                          |                       | 0.78     |
| Early  | 120                      | 54                    |          |
| Intermediate   | 68                       | 31                    |          |
| Advanced   | 71                       | 38                    |          |
| <b>HCT-CI score, median (range)</b>                  | 0 (0-7)                  | 1 (0-6)               | 0.38     |
| <b>Karnofsky PS, median (range)</b>                  | 90% (60-100)             | 90% (50-100)          | 0.25     |
| <b>Donor age, years, median (range)</b>              | 28 (19-56)               | 30 (20-52)            | 0.98     |
| <b>Donor gender, male, n</b>                         | 184                      | 91                    | 0.55     |
| <b>Female donor/male recipient, n</b>                | 40                       | 17                    | 0.68     |
| <b>Host/donor CMV serostatus, n</b>                  |                          |                       | 0.60     |
| Pos/pos  | 93                       | 49                    |          |
| Pos/neg  | 105                      | 47                    |          |
| Neg/pos  | 23                       | 7                     |          |
| Neg/neg  | 32                       | 18                    |          |
| <b>Type of conditioning, n</b>                       |                          |                       | 0.59     |
| MAC  | 186                      | 85                    |          |
| RIC  | 73                       | 38                    |          |
| <b>Source of stem cells, n</b>                       |                          |                       | 0.15     |
| PB   | 216                      | 95                    |          |
| BM   | 43                       | 28                    |          |
| <b>ATG-based GvHD prophylaxis, n</b>                 | 233                      | 112                   | 0.74     |

<sup>1</sup>shown are data for cut-off 2.665; data for cut-off 1.64 were not significantly different.

**Supplemental Table 5.** Patient, donor and transplant characteristics in in low risk and high risk DPB1 mismatched pairs according to the **Expression model**

|   | Low risk (N=153) | High risk (N=76) | p    |
|---|------------------|------------------|------|
| Median follow-up for survivors, years (range) | 3.5 (0.3-6)      | 3.3 (0.3-6)      | 0.59 |
| HSCT year, median (range)                     | 2013 (2012-2015) | 2013 (2012-2015) | 0.31 |
| Patient age, years, median (range)            | 49 (18-71)       | 49 (19-68)       | 0.98 |
| Patient gender, male, n                       | 93               | 45               | 0.82 |
| Type of diagnosis, n                          |                  |                  | 0.68 |
| AML or ALL                                    | 80               | 44               |      |
| MDS or MPN                                    | 27               | 13               |      |
| Lymphoma or Myeloma                           | 46               | 19               |      |
| Disease status at HSCT, n                     |                  |                  | 0.94 |
| Early   | 71               | 37               |      |
| Intermediate                                  | 39               | 19               |      |
| Advanced                                      | 43               | 20               |      |
| HCT-CI score, median (range)                  | 1 (0-6)          | 0 (0-7)          | 0.26 |
| Karnofsky PS, median (range)                  | 90% (50-100)     | 90% (70-100)     | 0.49 |
| Donor age, years, median (range)              | 28 (19-56)       | 29 (19-54)       | 0.19 |
| Donor gender, male, n                         | 105              | 53               | 0.86 |
| Female donor/male recipient, n                | 28               | 12               | 0.64 |
| Host/donor CMV serostatus, n                  |                  |                  | 0.47 |
| Pos/pos                                       | 62               | 24               |      |
| Pos/neg                                       | 53               | 33               |      |
| Neg/pos                                       | 13               | 5                |      |
| Neg/neg                                       | 21               | 12               |      |
| Type of conditioning, n                       |                  |                  | 0.73 |
| MAC   | 112              | 54               |      |
| RIC   | 41               | 22               |      |
| Source of stem cells, n                       |                  |                  | 0.09 |
| PB  | 129              | 57               |      |
| BM  | 24               | 19               |      |
| ATG-based GvHD prophylaxis, n                 | 136              | 72               | 0.15 |

**Supplemental Table 6.** Patient, donor and transplant characteristics in low risk or high risk DPB1 mismatched pairs according to the **DP2/DP5 model**

|  | <b>DP2 (N=118)</b> | <b>DP5 (N=31)</b> | <b>p</b> |
|--|--------------------|-------------------|----------|
| <b>Median follow-up for survivors, years (range)</b> | 3.4 (0.3-6.2)      | 2.8 (0.3-6.1)     | 0.39     |
| <b>H SCT year, median (range)</b>                    | 2013 (2012-2015)   | 2013 (2012-2015)  | 0.74     |
| <b>Patient age, years, median (range)</b>            | 49 (18-69)         | 45 (19-66)        | 0.16     |
| <b>Patient gender, male, n</b>                       | 74                 | 20                | 0.85     |
| <b>Type of diagnosis, n</b>                          |                    |                   | 0.67     |
| AML or ALL   | 58                 | 18                |          |
| MDS or MPN   | 22                 | 5                 |          |
| Lymphoma or Myeloma                                  | 38                 | 8                 |          |
| <b>Disease status at HSCT, n</b>                     |                    |                   | 0.83     |
| Early  | 57                 | 14                |          |
| Intermediate   | 28                 | 9                 |          |
| Advanced   | 33                 | 8                 |          |
| <b>HCT-CI score, median (range)</b>                  | 1 (0-6)            | 1 (0-5)           | 0.58     |
| <b>Karnofsky PS, median (range)</b>                  | 90% (50-100)       | 90% (70-100)      | 0.98     |
| <b>Donor age, years, median (range)</b>              | 28 (19-56)         | 29 (23-54)        | 0.09     |
| <b>Donor gender, male, n</b>                         | 84                 | 22                | 0.98     |
| <b>Female donor/male recipient, n</b>                | 20                 | 4                 | 0.41     |
| <b>Host/donor CMV serostatus, n</b>                  |                    |                   | 0.35     |
| Pos/pos  | 48                 | 8                 |          |
| Pos/neg  | 37                 | 14                |          |
| Neg/pos  | 11                 | 2                 |          |
| Neg/neg  | 18                 | 6                 |          |
| <b>Type of conditioning, n</b>                       |                    |                   | 0.07     |
| MAC  | 91                 | 19                |          |
| RIC  | 27                 | 12                |          |
| <b>Source of stem cells, n</b>                       |                    |                   | 0.39     |
| PB   | 96                 | 24                |          |
| BM   | 22                 | 7                 |          |
| <b>ATG-based GvHD prophylaxis, n</b>                 | 104                | 29                | 0.39     |

**Supplemental Table 7.** Univariate analysis for transplant outcomes and different models of DPB1 mismatch permissivity.<sup>1</sup>

|                                    | <b>3-y OS</b> | <b>3-y GRFS</b> | <b>3-y Relapse</b> | <b>3-y NRM</b> | <b>100-d aGvHD≥2</b> | <b>100-d aGvHD≥3</b> | <b>3-y cGvHD</b> | <b>3-y ext cGvHD</b> |
|------------------------------------|---------------|-----------------|--------------------|----------------|----------------------|----------------------|------------------|----------------------|
| <b>DPB1 allele matching status</b> |               |                 |                    |                |                      |                      |                  |                      |
| Matched (n=40)                     | 43 (26-59)    | 34 (20-49)      | 38 (23-54)         | 26 (13-40)     | 0                    | 0                    | 18 (8-31)        | 5 (1-16)             |
| Mismatched (n=382)                 | 53 (47-58)    | 32 (27-37)      | 29 (24-34)         | 27 (22-31)     | 23 (19-27)           | 8 (6-11)             | 29 (24-33)       | 9 (7-13)             |
| p                                  | 0.81          | 0.68            | 0.16               | 0.81           | <b>&lt;0.01</b>      | <b>0.05</b>          | 0.10             | 0.35                 |
| <b>TCE3</b>                        |               |                 |                    |                |                      |                      |                  |                      |
| Permissive mismatch (n= 208)       | 53 (46-60)    | 33 (26-40)      | 30 (24-37)         | 26 (20-32)     | 22 (16-28)           | 7 (4-11)             | 27 (21-33)       | 6 (4-10)             |
| Non Permissive mismatch (n=174)    | 52 (44-60)    | 30 (23-38)      | 27 (20-34)         | 28 (21-35)     | 24 (18-31)           | 9 (6-14)             | 31 (24-38)       | 13 (8-19)            |
| p                                  | 0.50          | 0.35            | 0.64               | 0.43           | 0.48                 | 0.57                 | 0.31             | <b>0.03</b>          |
| <b>TCE4</b>                        |               |                 |                    |                |                      |                      |                  |                      |
| Permissive mismatch (n=135)        | 60 (51-68)    | 36 (28-45)      | 30 (22-38)         | 21 (15-29)     | 21 (15-29)           | 7 (3-12)             | 26 (19-34)       | 4 (2-9)              |
| Non Permissive mismatch (n=247)    | 49 (42-55)    | 29 (24-35)      | 28 (22-34)         | 30 (24-36)     | 24 (19-29)           | 9 (5-12)             | 30 (25-37)       | 12 (8-17)            |
| p                                  | <b>0.05</b>   | <b>0.04</b>     | 0.96               | 0.09           | 0.56                 | 0.58                 | 0.3              | <b>0.01</b>          |
| <b>ΔFD</b>                         |               |                 |                    |                |                      |                      |                  |                      |
| <2.65 (n=259)                      | 54 (47-60)    | 31 (26-38)      | 28 (23-34)         | 27 (22-33)     | 23 (18-28)           | 8 (5-12)             | 28 (23-34)       | 9 (6-13)             |
| ≥2.65 (n=123)                      | 51 (41-60)    | 32 (24-41)      | 30 (22-39)         | 25 (18-33)     | 23 (16-31)           | 7 (4-13)             | 29 (21-38)       | 10 (6-17)            |
| p                                  | 0.83          | 0.71            | 0.57               | 0.71           | 0.90                 | 0.65                 | 0.88             | 0.75                 |
| <b>Expression model</b>            |               |                 |                    |                |                      |                      |                  |                      |
| low risk (n=153)                   | 56 (47-63)    | 27 (20-35)      | 34 (26-42)         | 23 (17-30)     | 16 (10-22)           | 5 (2-9)              | 29 (22-36)       | 9 (5-14)             |
| high risk (n=76)                   | 57 (45-68)    | 39 (28-50)      | 23 (14-34)         | 26 (16-36)     | 32 (22-43)           | 9 (4-17)             | 34 (24-45)       | 12 (6-20)            |
| p                                  | 0.95          | 0.23            | 0.23               | 0.81           | <b>&lt;0.01</b>      | 0.32                 | 0.30             | 0.42                 |
| <b>DP2/DP5 model</b>               |               |                 |                    |                |                      |                      |                  |                      |
| low risk (n=118)                   | 59 (49-67)    | 29 (21-38)      | 27 (19-36)         | 25 (17-33)     | 15 (9-22)            | 4 (2-9)              | 32 (24-41)       | 11 (6-17)            |
| high risk (n=31)                   | 62 (42-77)    | 39 (21-56)      | 31 (15-49)         | 23 (10-40)     | 43 (25-60)           | 20 (8-36)            | 26 (12-42)       | 16 (6-31)            |
| p                                  | 0.76          | 0.47            | 0.62               | 0.80           | <b>0.001</b>         | <b>0.01</b>          | 0.67             | 0.32                 |

<sup>1</sup>shown are mean percentages (range in parenthesis) for each outcome.

**Supplemental Table 8. Multivariate analysis of clinical factors associated with HCT outcomes.**

|  | OS                   |                            | GRFS                 |              | Relapse            |              | NRM                  |             | aGvHD $\geq$ 2              |     | aGvHD $\geq$ 3              |     | cGvHD                |                            | Ext cGvHD            |             |
|--|----------------------|----------------------------|----------------------|--------------|--------------------|--------------|----------------------|-------------|-----------------------------|-----|-----------------------------|-----|----------------------|----------------------------|----------------------|-------------|
|  | HR (95% CI)          | p                          | HR (95% CI)          | p            | HR (95% CI)        | p            | HR (95% CI)          | p           | HR (95% CI)                 | p   | HR (95% CI)                 | p   | HR (95% CI)          | p                          | HR (95% CI)          | p           |
| <b>TCE4<sup>1</sup>: NP Vs P</b>                             | <b>1.7 (1.1-2.4)</b> | <b>0.008</b>               | <b>1.4 (1.1-1.9)</b> | <b>0.01</b>  | 1.1 (0.7-1.7)      | 0.7          | <b>1.9 (1.1-3.2)</b> | <b>0.01</b> | 1.3 (0.8-2.1)               | 0.2 | 1.5 (0.7-3.2)               | 0.3 | <b>1.7 (1.1-2.6)</b> | <b>0.02</b>                | <b>3.6 (1.4-9.5)</b> | <b>0.01</b> |
| <b>Matched Vs P</b>  | <b>2.1 (1.2-3.7)</b> | <b>0.01</b>                | 1.5 (0.9-2.4)        | 0.09         | <b>2 (1.1-3.7)</b> | <b>0.03</b>  | 2 (0.9-4.8)          | 0.09        | Not applicable <sup>2</sup> |     | Not applicable <sup>2</sup> |     | 0.8 (0.3-2)          | 0.6                        | 0.9 (0.1-7.5)        | 0.9         |
| <b>Disease status: Intermediate Vs Early</b>                 | 1.4 (0.9-2.1)        | 0.09                       | 1.3 (0.9-1.8)        | 0.1          | 1.5 (0.9-2.5)      | 0.09         | 1.6 (0.9-2.7)        | 0.09        | 1.1 (0.6-1.9)               | 0.7 | 0.7 (0.3-1.7)               | 0.4 | 1.1 (0.7-1.8)        | 0.6                        | 2.4 (0.9-5.5)        | 0.09        |
| <b>Advanced Vs early</b>                                     | <b>2.3 (1.6-3.3)</b> | <b>&lt;10<sup>-3</sup></b> | <b>1.5 (1.1-2)</b>   | <b>0.01</b>  | <b>2 (1.2-3.2)</b> | <b>0.005</b> | <b>1.9 (1.2-3.3)</b> | <b>0.01</b> | 0.7 (0.4-1.3)               | 0.3 | 0.6 (0.2-1.6)               | 0.3 | 1 (0.6-1.7)          | 0.9                        | 1.2 (0.4-3.2)        | 0.7         |
| <b>Patient age</b>   | 1 (0.9-1.1)          | 0.2                        | 1 (0.9-1.1)          | 0.2          | 1 (0.9-1.1)        | 0.3          | 1 (0.9-1.1)          | 0.2         | 1 (0.9-1.1)                 | 0.4 | 1 (0.9-1.1)                 | 0.9 | 1 (0.9-1.1)          | 0.1                        | 1 (0.9-1.1)          | 0.9         |
| <b>HCTI-Score: <math>\geq</math>1 Vs 0</b>                   | 1.3 (0.9-1.9)        | 0.09                       | <b>1.4 (1.1-1.9)</b> | <b>0.008</b> | 1.1 (0.7-1.6)      | 0.7          | <b>1.6 (1.1-2.5)</b> | <b>0.04</b> | 1.2 (0.7-1.9)               | 0.5 | 1.5 (0.7-3.1)               | 0.3 | <b>2.2 (1.4-3.4)</b> | <b>&lt;10<sup>-3</sup></b> | <b>2.2 (1-5)</b>     | <b>0.05</b> |
| <b>Female donor to male recipient</b>                        | 1.1 (0.7-1.8)        | 0.6                        | 1.3 (0.9-1.1)        | 0.2          | 1.1 (0.6-2.1)      | 0.6          | 1.1 (0.6-2)          | 0.8         | 0.6 (0.3-1.3)               | 0.2 | 0.8 (0.3-2.3)               | 0.6 | 1.2 (0.7-2.1)        | 0.4                        | 2.4 (1.1-5.4)        | 0.04        |
| <b>CMV status: neg/neg Vs other</b>                          | 0.7 (0.4-1.2)        | 0.2                        | 0.9 (0.6-1.4)        | 0.7          | 0.6 (0.3-1.3)      | 0.2          | 0.8 (0.4-1.7)        | 0.6         | 1.1 (0.5-2.1)               | 0.9 | 1.3 (0.5-3.6)               | 0.6 | 1 (0.5-2)            | 0.9                        | 1 (0.4-2.8)          | 0.9         |
| <b>Conditioning: MAC Vs RIC</b>                              | 1.3 (0.9-1.9)        | 0.1                        | 1.1 (0.8-1.5)        | 0.5          | 1 (0.6-1.6)        | 0.9          | 1.3 (0.8-2.1)        | 0.4         | 1.4 (0.8-2.4)               | 0.2 | 1.9 (0.7-5.1)               | 0.2 | 1.1 (0.7-1.7)        | 0.8                        | 0.5 (0.2-1.1)        | 0.08        |
| <b>Stem cell source: PB Vs BM</b>                            | 1.1 (0.7-1.6)        | 0.8                        | 1.1 (0.8-1.6)        | 0.6          | 1 (0.6-1.7)        | 0.9          | 1.1 (0.6-1.9)        | 0.8         | 1.4 (0.7-2.7)               | 0.3 | 2.4 (0.7-8.4)               | 0.2 | 0.8 (0.4-1.3)        | 0.3                        | 0.6 (0.2-1.7)        | 0.4         |
| <b>ATG use</b>   | 1.2 (0.5-2.7)        | 0.7                        | 0.9 (0.5-1.7)        | 0.8          | 2.6 (0.6-11)       | 0.2          | 1 (0.3-2.8)          | 0.9         | 0.5 (0.2-1.4)               | 0.2 | 0.4 (0.1-1.4)               | 0.1 | 1 (0.4-2.4)          | 0.9                        | 0.9 (0.2-3.2)        | 0.8         |
| <b>Overall HLA-matching: 9/10 Vs 10/10</b>                   | 1.8 (1-3.3)          | 0.06                       | 1.1 (0.7-1.7)        | 0.6          | 2 (0.9-4.2)        | 0.07         | 1.5 (0.7-3.3)        | 0.3         | 1.4 (0.6-3)                 | 0.5 | 1.2 (0.4-4.1)               | 0.8 | 0.8 (0.4-1.4)        | 0.4                        | 1.5 (0.3-6.6)        | 0.6         |
| <b>Center effect: <math>\geq</math>10 HCT/year Vs &lt;10</b> | 0.9 (0.7-1.3)        | 0.7                        | 1 (0.7-1.3)          | 0.8          | 0.8 (0.5-1.3)      | 0.4          | 0.9 (0.5-1.4)        | 0.6         | 0.9 (0.6-1.6)               | 0.9 | 0.7 (0.3-1.5)               | 0.3 | 1.1 (0.7-1.7)        | 0.7                        | 1.9 (0.8-4.6)        | 0.2         |

<sup>1</sup>TCE4 NP, P and matched: N= 247, 135 and 40, respectively.<sup>2</sup>Not applicable since no cases of aGvHD occurred in the DPB1 matched cohort.

Shown are the data for the TCE4 functional model as main effect term and covariates as described in Statistical methods.